MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
Five-year collaboration intended to advance PD-1/VEGF bispecific in several solid tumors across multiple clinical trials
2024-07-25
(Press-News.org) HOUSTON and MIAMI ― The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover additional opportunities for ivonescimab, including several tumors outside of its current development plan. MD Anderson will lead multiple clinical trials in several tumor types to evaluate the safety and potential clinical benefit of ivonescimab, including the possibility of identifying biomarkers through additional research activities.
“We are excited to collaborate with MD Anderson to provide unique insights and expertise to further broaden the development of ivonescimab,” said Allen S. Yang, M.D., Ph.D., chief medical officer of Summit. “This collaboration will help accelerate the growing clinical development efforts for ivonescimab and help bring this innovative advancement on immunotherapy and anti-angiogenic standards to as many patients who may benefit as possible.”
Early work may include certain types of renal cell carcinoma, colorectal cancer, skin cancer, breast cancer and glioblastoma, which has the potential to rapidly expand the breadth and depth of the ivonescimab development program. The bispecific antibody has shown significant promise in recent read-outs from the randomized Phase III non-small cell lung cancer clinical trials, HARMONi-A and HARMONi-2, conducted by Summit’s partner, Akeso, in addition to promising Phase II data in other solid tumors.
“Through our extensive clinical research efforts, we are committed to bringing impactful new medicines to patients in need as rapidly as possible,” said Christopher Flowers, M.D., division head of Cancer Medicine at MD Anderson. “We are pleased to be collaborating with Summit to broaden the clinical development efforts of ivonescimab and its unique mechanism of action to support our mutual goal to improve the therapeutic options for patients with cancer.”
MD Anderson and Summit will collaborate on the design and conduct of preclinical and clinical studies, with oversight from a joint steering committee. This research is expected to begin later this year.
Read this press release in the MD Anderson Newsroom.
- 30 -
About Summit
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol "SMMT"). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK. For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-07-25
Scientists have known from ice core research that it's easier to melt an ice sheet than to freeze it up again. Now, they know at least part of the reason why, and it has to do with ice's "sponginess," according to a new study published July 24 in The Cryosphere.
The study uses a physics-based numerical model to assess the impacts of warming and cooling on firn, the porous layer between snow and glacial ice, over the entire Greenland Ice Sheet. Megan Thompson-Munson, a CIRES and ATOC PhD student, led the study alongside ...
2024-07-25
Houston, Texas, July 25, 2024 – The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR’s TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart.
The first-in-human clinical ...
2024-07-25
University of Washington Researchers Take Flight with New Insights on Bat Evolution
Video Interview with Authors - https://youtu.be/6rogrh2_HN0
In new research published in PeerJ Life & Environment, researchers from the University of Washington, University of Texas at Austin and Oregon Institute of Technology, led by undergraduate student Abby Burtner, have advanced our understanding of the evolutionary origins of flight in bats. The study, titled "Gliding toward an Understanding of the Origin of Flight in Bats," employs phylogenetic comparative methods to explore the evolutionary transition from gliding to powered flight in these unique mammals.
Bats ...
2024-07-25
HOUSTON – (June 25, 2024) – Rice University President Reginald DesRoches joined Rice360 Institute for Global Health Technologies Co-Director Maria Oden and Rice360 supporters on a trip to Africa this summer marking significant milestones on the road to ending preventable newborn deaths in the sub-Saharan region. Rice360 is one of 22 organizations in the Newborn Essential Solutions and Technologies (NEST360) international alliance, and this trip signified Rice’s continued collaboration ...
2024-07-25
4D Medicine, a spin-out from the Universities of Birmingham and Warwick has raised £3.4m ($4.4m) in a Series A investment.
The funding round was backed by Oshen Holdings, DSW Ventures, SFC Capital, Boundary Capital and private investors including several leading scientists and surgeons. It will enable the company to complete pre-clinical testing of its first product range and seek FDA clearance for entry into the US market.
4D is a UK-based company whose innovative biomaterial has potential to be used for a wide range of 3D printed implants and surgical devices. Its product 4Degra is a resorbable biomaterial that is being used to develop ...
2024-07-25
The findings, published today in Nature Ecology & Evolution, sheds light on some core principles of the evolution of modern biodiversity.
In current oceans, molluscs such as clams, oysters, and snails are hugely diverse, with over 50,000 species, whereas brachiopods are rare by comparison with only 394 species known. But this was not always the case. The team have found that brachiopods were evolving new shell shapes and ecological behaviours following the end-Permian mass extinction which compromised their numbers.
“In the Palaeozoic, from 540 to 250 million years ago, brachiopods ruled the seabed,” ...
2024-07-25
In a scientific breakthrough, an international research team from Germany's Forschungszentrum Jülich and Korea's IBS Center for Quantum Nanoscience (QNS) developed a quantum sensor capable of detecting minute magnetic fields at the atomic length scale. This pioneering work realizes a long-held dream of scientists: an MRI-like tool for quantum materials.
The research team utilized the expertise of bottom up single-molecule fabrication from the Jülich group while conducting experiments at QNS, utilizing the Korean team’s leading-edge ...
2024-07-25
PISCATAWAY, NJ – Probably everyone has heard the conventional wisdom that a glass of wine a day is good for you--or you’ve heard some variation of it. The problem is that it’s based on flawed scientific research, according to a new report in the Journal of Studies on Alcohol and Drugs.
Over the years, many studies have suggested that moderate drinkers enjoy longer lives with lower risks of heart disease and other chronic ills than abstainers do. That spurred the widespread belief that alcohol, in moderation, can be a health tonic. However, not all studies have painted such a rosy picture--and the ...
2024-07-25
The proliferation of all things digital doesn’t mean that printing technology is no longer relevant. In fact, printing technology is required to make the semiconductors necessary for the digital world. And as an Osaka Metropolitan University-led team has shown using a new printing technique, printable magnetic devices for high-density data storage might soon be realized.
Dr. Ken-ichi Yuyama, a lecturer at the Graduate School of Science, and his colleagues report in APL Materials on the development of a new type of laser-induced forward transfer ...
2024-07-25
A new major study by the University of Eastern Finland, the University of Oulu and Neurocenter Finland explored early-onset dementia in the working-age population in Finland. The study cohort was one of the largest in the world to date, and the findings were published on 24th of July 2024 in Neurology®, the medical journal of the American Academy of Neurology.
Current epidemiological data on early-onset dementia is scarce and based on small study cohorts, with no recent data from Finland available. For the present ...
LAST 30 PRESS RELEASES:
[Press-News.org] MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
Five-year collaboration intended to advance PD-1/VEGF bispecific in several solid tumors across multiple clinical trials
